Beauty
Health
Lifestyle
Medicine
Biowatch
Column
Kormedi.com TV
Notice
Newsletter subscription
Beauty
Health
Lifestyle
Medicine
Biowatch
Column
Kormedi.com TV
Notice
Languages
ENGLISH
English (US)
ASIAN
Монгол
日本語
Tiếng Việt
Bahasa Indonesia
中文 (简体, 中国大陆)
EUROPEAN
Русский
Español (España)
Français (France)
MIDDLE_EAST_AFRICA
العربية
Search results for "K-Bio"
Home
South Korean Biotechs Race to Conquer the Untapped Global MASH Market
Fat accumulation in the liver can trigger severe inflammation even in individuals who completely abstain from alcohol.
06/05/2026, 04:23 ET
Osteoporosis Drugs That Can Be Hard to Keep Taking…Could ‘Sleeping Bone Cells’ Offer a Breakthrough?
Some patients need to rebuild bone quickly. These are people at high fracture risk—those who have already broken a bone once, or whose bone mineral...
04/21/2026, 05:32 ET
New Biologic Drug Lands in Korea: Expanded Relief for Chronic Rhinosinusitis and Nasal Polyps
A biologic medication previously recognized for its effectiveness in treating severe asthma is now offering a new...
04/09/2026, 04:59 ET
A Milestone for K-Bio: Celltrion’s Truxima Surpasses Global Blockbuster Rituxan in U.S. Prescriptions
Truxima , a blood cancer treatment developed by Celltrion, has become the first Korean-made biosimilar to rank number...
04/09/2026, 01:13 ET
HK inno.N’s ‘Ecnoglutide’: Can a Late Entrant’s “Hidden Card” Reshape the Obesity Market?
HK inno.N is fast-tracking the South Korean launch of ecnoglutide, a GLP-1 receptor agonist licensed from China’s...
03/23/2026, 02:59 ET
Idience Targeted Cancer Drug Candidate ‘Venadaparib’ Granted FDA Fast Track Designation
Idience, a novel anticancer drug developer under the Ildong Pharmaceutical Group, announced on the 18th that its...
03/18/2026, 03:08 ET
Kyungbo Pharmaceutical Passes U.S. FDA On-Site Inspection at Asan Plant
Kyungbo Pharmaceutical announced on the 18th that it passed an on-site manufacturing inspection by the U. S.
03/18/2026, 03:08 ET
Celltrion: “Zymfentra prescriptions surging in the U.S.… growth is accelerating in earnest”
Celltrion’s subcutaneous formulation for autoimmune diseases, “Zymfentra,” which launched in the United States, has...
03/18/2026, 03:08 ET
Huwons Lab SC Formulation Change Platform, Will It Succeed in the Market?
Huwons Global's subsidiary Huwons Lab is challenging the formulation change platform business that converts intravenous...
03/17/2026, 01:44 ET
Hanmi Pharmaceutical, CEO Park Jae-hyun Steps Down: Hwang Sang-yeon Appointed as New CEO Candidate
Hanmi Science is replacing CEO Park Jae-hyun of its subsidiary Hanmi Pharmaceutical and forming a new board of...
03/17/2026, 01:44 ET
Previous
2
3
4
5
6
Next